CMS plans to launch a new drug payment model for state Medicaid programs, the first of potentially multiple pricing models under President Donald Trump’s “most

The FDA told Biohaven its study using real-world data “would likely be inadequate to provide substantial evidence of effectiveness” when it was proposed, according to

Gilead’s Trodelvy failed to meet the primary endpoint in a Phase 3 trial for certain breast cancer patients, marking another setback for a key drug

Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for

Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore: ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is